The company's financial position is increasingly vulnerable, with retained earnings plummeting to -$460.3M and cash reserves declining to $20.3M as of 2026Q1.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Total Current Assets | 28.47M | 34.81M | 40.53M | 47.33M | 65.52M | 45.6M | 34.13M | 22.91M | 13.31M | 6.05M | 2.94M | 4.29M | 2.06M | 2.93M | 1.67M |
| Cash & Short-Term Investments | 20.26M | 26.25M | 28.46M | 36.8M | 49.36M | 36M | 28.59M | 20.59M | 11M | 3.98M | 1.32M | 2.75M | 1.54M | 2.42M | 1.25M |
| Cash Only | 20.26M | 26.25M | 27.76M | 36.8M | 49.36M | 36M | 28.59M | 20.59M | 11M | 3.72M | 1.09M | 2.67M | 1.45M | 2.26M | 1.23M |
| Short-Term Investments | 0 | 0 | 697K | 0 | 0 | 0 | 0 | 0 | 0 | 258K | 225K | 80K | 83K | 153.6K | 21.57K |
| Accounts Receivable | 2.22M | 2.67M | 5.35M | 3.64M | 6.42M | 1.79M | 1.7M | 712K | 234K | 435K | 290K | 22K | 33K | 51.48K | 71.43K |
| Days Sales Outstanding | 54.49 | 43.6 | 72.24 | 65.33 | 84.68 | 31.78 | 82.1 | 34.38 | 11.55 | 30.71 | 37.76 | 9.76 | 236.18 | - | - |
| Inventory | 4.17M | 4.32M | 4.75M | 5.06M | 7.96M | 6.23M | 2.29M | 1.41M | 1.38M | 1.18M | 888K | 601K | 234K | 0 | 0 |
| Days Inventory Outstanding | 178.04 | 162.51 | 125.96 | 128.59 | 161.32 | 182.68 | 165.31 | 104.01 | 89.29 | 111.99 | 96.35 | 130.73 | 37.56 | - | - |
| Other Current Assets | 1.81M | 0 | 175K | 292K | 887K | 0 | 187K | 0 | 251K | 258K | 0 | 291K | 94K | 0 | 13.42K |
| Total Non-Current Assets | 74.81M | 75.27M | 78.36M | 49.06M | 53.67M | 55.17M | 1.28M | 1.65M | 776K | 911K | 936K | 790K | 1.02M | 1.19M | 648.91K |
| Property, Plant & Equipment | 1.12M | 0 | 1.77M | 1.87M | 1.99M | 989K | 1.07M | 1.41M | 733K | 869K | 901K | 749K | 978K | 1.14M | 617.36K |
| Fixed Asset Turnover | 21.66x | - | 15.24x | 10.91x | 13.87x | 20.74x | 7.05x | 5.35x | 10.09x | 5.95x | 3.11x | 1.10x | 0.05x | - | - |
| Goodwill | 57.43M | 57.43M | 57.43M | 41.64M | 41.64M | 41.64M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 15.47M | 15.93M | 18.76M | 5.4M | 9.92M | 12.46M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 239K | 80K | 0 | 6K | 6K | 20K | 0 | 17K | 43K | 42K | 35K | 41K | 0 | 0 | 0 |
| Other Non-Current Assets | 720K | 1.83M | 392K | 143K | 117K | 57K | 205K | 224K | 0 | 0 | 0 | 0 | 47K | 41.17K | 31.55K |
| Total Assets | 103.28M | 110.08M | 118.88M | 96.39M | 119.19M | 100.77M | 35.41M | 24.57M | 14.09M | 6.96M | 3.87M | 5.08M | 3.08M | 4.12M | 2.32M |
| Asset Turnover | 0.19x | 0.20x | 0.23x | 0.21x | 0.23x | 0.20x | 0.21x | 0.31x | 0.52x | 0.74x | 0.72x | 0.16x | 0.02x | - | - |
| Asset Growth % | -22.3% | -7.41% | 23.34% | -19.13% | 18.28% | 184.61% | 44.11% | 74.38% | 102.52% | 79.67% | -23.73% | 64.78% | -25.14% | 77.75% | - |
| Total Current Liabilities | 9.36M | 9.32M | 16.64M | 12.49M | 19.35M | 14.38M | 7.03M | 5.22M | 5.16M | 3.02M | 2.92M | 1.69M | 1.62M | 1.51M | 566.75K |
| Accounts Payable | 3.47M | 2.93M | 3.04M | 1.13M | 2.32M | 5.11M | 2.48M | 1.66M | 2.57M | 1.85M | 1.81M | 978K | 708K | 586K | 250.35K |
| Days Payables Outstanding | 131.25 | 110.25 | 80.7 | 28.73 | 47.08 | 149.85 | 178.79 | 121.81 | 166.91 | 175.17 | 196.61 | 212.74 | 113.64 | 15.77 | - |
| Short-Term Debt | 378K | 430K | 5.45M | 3.95M | 8.82M | 266K | 0 | 317K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 2.8M | 714K | 1.58M | 997K | 1.32M | 1.2M | 1.22M | 1.22M | 736K | 0 | 0 | 31K | 24K | 0 | 0 |
| Other Current Liabilities | 5.01M | 5.25M | 0 | 4.07M | 2.19M | 4.4M | 880K | 887K | 880K | 0 | 0 | 434K | 679K | 591.4K | 84.08K |
| Current Ratio | 3.04x | 3.73x | 2.44x | 3.79x | 3.39x | 3.17x | 4.85x | 4.39x | 2.58x | 2.01x | 1.00x | 2.54x | 1.27x | 1.95x | 2.94x |
| Quick Ratio | 2.60x | 3.27x | 2.15x | 3.38x | 2.98x | 2.74x | 4.53x | 4.12x | 2.31x | 1.61x | 0.70x | 2.18x | 1.13x | 1.95x | 2.94x |
| Cash Conversion Cycle | 101.28 | 95.86 | 117.51 | 165.2 | 198.92 | 64.6 | 68.61 | 16.58 | -66.07 | -32.47 | -62.49 | -72.25 | 160.09 | - | - |
| Total Non-Current Liabilities | 31.54M | 32.83M | 30.23M | 25.75M | 19.84M | 846K | 222K | 455K | 0 | 1K | 7.49M | 2.61M | 4M | 2.7M | 2.82M |
| Long-Term Debt | 30.93M | 30.75M | 23.47M | 24.59M | 18.11M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 2.27M | 571K | 765K | 885K | 827K | 21K | 222K | 455K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 106K | 1.51M | 5.99M | 276K | 910K | 825K | 0 | 0 | 0 | 1K | 7.49M | 2.61M | 4M | 2.7M | 2.82M |
| Total Liabilities | 40.9M | 42.15M | 46.87M | 38.24M | 39.19M | 15.22M | 7.26M | 5.67M | 5.16M | 3.02M | 10.41M | 4.3M | 5.62M | 4.2M | 3.38M |
| Total Debt | 31.82M | 31.75M | 30.19M | 29.54M | 28.05M | 287K | 532K | 772K | 0 | 0 | 0 | 2.36M | 2.76M | 0 | 0 |
| Net Debt | 11.55M | 5.5M | 2.43M | -7.26M | -21.31M | -35.71M | -28.06M | -19.81M | -11M | -3.72M | -1.09M | -314K | 1.3M | -2.26M | -1.23M |
| Debt / Equity | 0.51x | 0.47x | 0.42x | 0.51x | 0.35x | 0.00x | 0.02x | 0.04x | - | - | - | 3.03x | - | - | - |
| Debt / EBITDA | -0.59x | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.21x | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -7.68x | -10.91x | -601.50x | -92.04x | -22.48x | -886.60x | -610.27x | -655.74x | -982.67x | -84.32x | -541.60x | -349.91x | - | - | - |
| Total Equity | 62.38M | 67.92M | 72.02M | 58.14M | 80M | 85.55M | 28.15M | 18.89M | 8.93M | 3.94M | -6.54M | 777K | -2.54M | -86.38K | -1.07M |
| Equity Growth % | 1.04% | -5.69% | 23.86% | -27.32% | -6.49% | 203.89% | 48.99% | 111.7% | 126.47% | 160.25% | -941.83% | 130.61% | -2838.15% | 91.92% | - |
| Book Value per Share | 1.26 | 1.37 | 1.78 | 2.05 | 3.38 | 5.16 | 4.72 | 8.34 | 7.62 | 8.19 | -25.14 | 8.19 | -105.28 | -8.49 | -96.39 |
| Total Shareholders' Equity | 62.38M | 67.92M | 72.02M | 58.14M | 80M | 85.55M | 28.15M | 18.89M | 8.93M | 3.94M | -6.54M | 777K | -2.54M | -86.38K | -1.07M |
| Common Stock | 4K | 4K | 4K | 3K | 3K | 2K | 0 | 0 | 8K | 7K | 6K | 5K | 2K | 2.01K | 1.45K |
| Retained Earnings | -460.33M | -452.08M | -390.34M | -349.36M | -285.85M | -222.01M | -143.25M | -110.14M | -89.25M | -70.96M | -54.96M | -43.35M | -36.06M | -20M | -6.07M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -440K | -477K | -286K | -432K | -97K | -824.9K | -24.82K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Insufficient capital runway
As reported in recent financial statements, DarioHealth's cash and equivalents have declined to $20.3M in 2026Q1 from a peak of $36.8M in 2023Q4, indicating a tightening liquidity buffer that may necessitate external financing to sustain operations given the company's ongoing negative cash flow profile.
The current ratio of 3.04 suggests adequate short-term coverage, yet this metric is heavily influenced by the composition of current assets which may not be readily convertible to cash. Investors should monitor the burn rate closely, as the rapid depletion of cash reserves relative to operating losses suggests that the company's financial flexibility is narrowing significantly.
Based on reported figures, goodwill accounts for $57.4M of the company's $103.3M in total assets as of 2026Q1, representing a substantial portion of the balance sheet that warrants further investigation regarding potential impairment risks given the recent 17.31% decline in top-line revenue.
The heavy reliance on intangible assets suggests that the company's book value is sensitive to the performance of past acquisitions. If the B2B pivot fails to generate the anticipated growth, the carrying value of these assets may become increasingly difficult to justify, potentially leading to non-cash charges that would further erode equity.
According to recent SEC filings, DarioHealth's retained earnings have plummeted to -$460.3M as of 2026Q1, reflecting a persistent pattern of net losses that continues to weigh on the company's total equity base and signals a long-term struggle to achieve operational self-sufficiency.
The consistent accumulation of deficits highlights the structural challenges in the company's business model. While the equity base remains positive, the trend of deepening losses suggests that shareholder value is being systematically depleted, increasing the likelihood of future dilutive equity raises to support the balance sheet.
As disclosed in quarterly balance sheets, DarioHealth maintains a debt-to-equity ratio of 0.51, which appears relatively conservative; however, this low leverage is likely a function of limited access to traditional credit markets rather than a strategic choice to avoid debt-related interest expenses.
While the debt load of $31.8M is not immediately overwhelming, the company's inability to generate positive operating cash flow makes even modest debt obligations a potential burden. The lack of significant debt suggests that the company has relied primarily on equity financing to fund its operations, which may limit future financing options.
Quick answers to the most common questions about buying DRIO stock.
As of 2025, DarioHealth Corp. (DRIO) had total assets of $110.1M including $34.8M in current assets.
DarioHealth Corp. (DRIO) carries total debt of $31.7M, offset by $26.2M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
DarioHealth Corp. (DRIO) has total shareholders' equity (book value) of $67.9M ($1.37 book value per share). Book value represents the net worth of the company belonging to common stock holders.
DarioHealth Corp. (DRIO) reported a current ratio of 3.73x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.